Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

With a market cap of $62.4 billion, Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and ...

We recently published a list of 11 Blue Chip Stocks to Invest in at 52-Week Lows. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against ...

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $831.43, with a high estimate of $1013.00 and a low estimate of $547.00. Highlighting a 8.86% ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on Regeneron (REGN – Research Report), with a price ...

In a report released on April 11, Salveen Richter from Goldman Sachs maintained a Buy rating on Regeneron (REGN – Research Report), with a ...

Despite the more favorable entry price, we don't have much confidence in Regeneron. Here are three reasons why you should be careful with REGN and a stock we'd rather own. Founded by scientists ...

The stock's rise snapped a four-day losing streak.

REGN stock was down more than 2% on Apr. 8 ... a “Hold,” and one suggests a “Moderate Sell” rating. Its mean price target of $927.08 indicates a robust 67.2% upside potential from ...